This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Bouaziz, H. Articles by Laxenaire, M.-C. Search for Related Content PubMed PubMed Citation Articles by Bouaziz, H. Articles by Laxenaire, M.-C.

---

REGIONAL ANESTHESIA AND PAIN MANAGEMENT

Sufentanil Does Not Prolong the Duration of Analgesia in a Mepivacaine Brachial Plexus Block: A Dose Response Study

Hervé Bouaziz, PhD, MD^*, Brian P. Kinirons, FFARCSI, Dioukamalou Macalou, MD^*, Michel Heck, MD^*, François Dap, MD, Dan Benhamou, MD^§, and Marie-Claire Laxenaire, MD^*

*Département d’Anesthésie-Réanimation, CHU Hôpital Central; Département d’Anesthésie-Réanimation, CHU de Bicêtre; Département de Chirurgie de la main, CHU Nancy - Hôpital Jeanne d’Arc, Dommartin lès Toul; and §Département d’Anesthésie-Réanimation, CHU de Bicêtre - Hôpital Antoine Béclère, Cedex, France

Address correspondence and reprint requests to Dr. Hervé Bouaziz, Département d’Anesthésie-Réanimation, CHU Hôpital Central-Case Officielle No. 34, 54035 Nancy Cedex, France. Address e-mail to h.bouaziz{at}chu-nancy.fr

To date, results of studies evaluating the efficacy of opioids and local anesthetic combinations in the brachial plexus are inconclusive. We examined whether increasing sufentanil in doses of 5, 10, and 20 µg decreased onset time or increased duration of an axillary brachial plexus block. Ninety-two patients scheduled for carpal tunnel release under axillary brachial plexus block were enrolled in the study. Patients were randomized to receive axillary plexus block with 40 mL 1.5% mepivacaine and saline (Group 1), sufentanil 5 µg (Group 2), 10 µg (Group 3), or 20 µg (Group 4). Onset and duration of sensory and motor block were measured. Opioid-related side effects were recorded. The addition of sufentanil did not improve speed of onset or increase the duration of sensory or motor block. Paradoxically, duration of sensory and motor block was longest in the control group: sensory, 241 min (188–284) and motor, 234 min (128–305), and decreased with increasing doses of sufentanil in Group 4: sensory, 216 min (115–315) and motor, 172 min (115–260) (P < 0.05). Side effects occurred in 55% of patients belonging to Groups 2 and 4, and in 60% of the patients in Group 3. In contrast, only 10% of the patients reported side effects in the control group. We conclude that sufentanil added to mepivacaine does not increase the onset or prolong the duration of an axillary plexus block. Furthermore, the addition of sufentanil was associated with a frequent incidence of side effects.

Implications: This study demonstrates that the addition of sufentanil in a dose-dependent manner to 1.5% mepivacaine in the axillary plexus does not improve onset or duration of blockade, and that this admixture is associated with an increased incidence of side effects.